IACUC and IRB Oversight: The Compliance Context for Research

Spend any time in research literature and you meet two acronyms early: IRB and IACUC. They turn up in the methods section of nearly every published study involving people or animals, usually as one dry sentence confirming a committee signed off before the work began. What that sentence never explains is which committee had authority over what, where the authority came from, or — the question that trips up more researchers than any other — when neither committee is involved at all. One note before any of it: the compounds Optides supplies are for research use only, and are not for human or animal consumption of any kind.

What follows is educational background on the oversight system that shapes how research compliance language gets written. It isn't guidance for conducting a study, and nothing here describes any use of a research compound in a person or an animal.

Two Committees, Two Jobs

The short version: one committee protects people, the other protects animals, and they were built decades apart for different reasons.

The Institutional Review Board

An Institutional Review Board reviews research involving human participants, and its mandate is their rights and welfare. The composition rules are specific rather than advisory. Federal regulations at 21 CFR 56.107 require a minimum of five members, including at least one scientist and one non-scientist, with diversity of background, expertise, and institutional affiliation. That non-scientist seat isn't decoration. It's there so a protocol has to make sense to someone who isn't already inside the discipline. Institutions running federally funded human research register with the Office for Human Research Protections and maintain a Federalwide Assurance documenting what they've committed to.

The Institutional Animal Care and Use Committee

An Institutional Animal Care and Use Committee reviews activities involving animals, asking two things at once: is the use scientifically justified, and does the care meet standards. Under 9 CFR 2.31 the committee needs a chair, a veterinarian with laboratory animal training or experience, and at least one member with no institutional affiliation beyond committee service. The institution also needs an Animal Welfare Assurance number from the NIH Office of Laboratory Animal Welfare, commonly called OLAW. Without that number, no federally funded animal research may proceed at all. It functions as a license to operate, not a formality.

The Legal Scaffolding Behind Each Committee

The split between the two is historical. Each committee is the local implementation of a different federal instrument, written at a different time and enforced by a different agency. Neither writes its own rules, which is why committee requirements look broadly similar across institutions and differ only in the details.

Human subjects: the Common Rule and the FDA's parallel track

The governing instrument is 45 CFR 46, known as the Common Rule, established in 1991 and traceable to the National Research Act of 1974 and the Belmont Report's three principles: respect for persons, beneficence, and justice. Twenty federal departments and agencies are signatories, each citing it in their own part of the code. Dedicated subparts add protections for pregnant women and fetuses, prisoners, and children.

The framework was substantially revised effective July 2018. Multi-site studies now fall under a single-IRB mandate instead of duplicating review at every location, broad consent became available for future use of biospecimens, continuing review was dropped for certain minimal-risk categories, and the exempt list expanded. Separately, when a study involves a test article the FDA regulates, the agency's own requirements at 21 CFR 50 and 21 CFR 56 attach on top of the Common Rule.

Animals: the Animal Welfare Act and Public Health Service Policy

On the animal side there are two overlapping sources. The Animal Welfare Act of 1966 is enforced by the USDA's Animal and Plant Health Inspection Service, with licensing for dealers and exhibitors and registration for research facilities. Its coverage has a well-known gap: birds, laboratory rats of the genus Rattus, laboratory mice of the genus Mus, farm animals in agricultural research, and all cold-blooded animals sit outside the Act entirely. Rodents are by far the most-used research species, so that gap covers most animal research in the country.

The 1985 Food Security Act amendments created the IACUC mandate itself and added psychological well-being as something committees must weigh. Public Health Service Policy then fills the species gap for federally funded work, reaching all live vertebrate animals regardless of genus, and accreditation by AAALAC International adds a voluntary third layer on top.

The Three Review Pathways

Not every protocol gets the same scrutiny. Review level scales with risk — and crucially, the investigator doesn't get to choose it.

Exempt determination

Six federally designated categories can be exempt: research in established educational settings, certain surveys and interviews, analysis of existing non-identifiable data, food quality evaluation, and a few others. Here's the point that causes the most trouble. Exemption is a determination the IRB issues, not a conclusion the investigator reaches independently. The protocol still gets submitted, and an IRB representative confirms the exemption before work begins. The stakes are high because retrospective review isn't available — a determination that was never requested can't be granted after the fact, which can leave finished data unpublishable and unusable for a regulatory submission.

Expedited review

Minimal-risk studies and minor modifications to already-approved work can take the expedited path, handled by the chair or designated reviewers rather than the full committee. Typical examples include prospective collection of hair or saliva, blood draws from healthy volunteers, or analysis of existing pathological specimens. One structural limit matters here: in the U.S. system a protocol cannot be disapproved through expedited review. A reviewer with concerns has to send it to the full committee.

Full committee review

Anything above minimal risk requires the convened board — studies using investigational drugs, work involving vulnerable populations such as children or prisoners, prospective invasive tissue collection, or procedures involving sedation. Quorum rules require majority attendance with at least one member focused on non-scientific aspects.

Four questions settle the pathway: Is this a systematic investigation designed to contribute to generalizable knowledge? Does it involve human subjects? Does it qualify for exemption? And if not, what risk level applies?

Where Research-Grade Compounds Actually Sit on This Map

For most laboratory work on a research-grade compound, the honest answer is that neither committee is the gatekeeper. Understanding why clarifies what the labeling on such material is actually describing.

The federal test is whether an investigator is engaged in research involving human subjects. That happens when they manipulate a participant's environment, interact with participants, obtain identifiable private health information, or receive federal funding for non-exempt work. There's also a specific carve-out worth knowing: laboratory personnel analyzing de-identified specimens with no capability to re-identify them are generally not engaged in research, with a narrow exception when the principal investigator is affiliated with that laboratory and the study is federally funded.

Run that test against ordinary bench work — in-vitro characterization, analytical chemistry, stability studies, comparison against a reference standard — and nothing triggers either committee's jurisdiction. No human participants, no covered animals. The line gets crossed at one specific point: the moment a compound would enter a living human participant or a covered animal, the relevant committee has authority and prior approval becomes mandatory.

This is precisely why material intended for laboratory characterization carries research use only labeling and the "not for human use" label. Those statements describe a lane that sits outside both committees' remit by design. Institutions often add their own overlay anyway — biosafety registration, chemical hygiene review, hazardous materials sign-off — so "no IRB or IACUC protocol" rarely means "no paperwork."

Where GLP Ends and Committee Review Begins

Good Laboratory Practice and committee review get conflated constantly, but they answer different questions. One asks whether data can be trusted. The other asks whose welfare is at stake.

Good Laboratory Practice under 21 CFR Part 58 governs nonclinical laboratory safety studies intended to support an application for a research or marketing permit. It imposes structural roles rather than scientific judgments: a named Study Director carries overall responsibility for the study, and a Quality Assurance Unit operates independently of study personnel, inspecting facilities, reviewing raw data, and keeping its own records.

What Part 58 leaves out is as informative as what it covers. Basic exploratory research seeking new scientific principles falls outside it. So do preliminary investigations with no predetermined endpoints, studies run purely for internal decision-making, and clinical investigations in humans. The practical read: GLP asks whether a study can be reconstructed and defended, while IRB and IACUC ask whether it's justified with respect to the participants or animals involved. A single animal safety study can sit under both frameworks at once — IACUC for the animals, GLP for the data integrity.

What Oversight Looks Like After Approval

Approval is a starting line. Both systems carry continuing obligations on fixed clocks, and lapses are themselves reportable events.

On the animal side

Committees must inspect every animal facility and review the institution's animal care program at least every six months, and each protocol gets a fresh de novo review at least every three years. An annual report goes to OLAW, and significant noncompliance must be reported with documented corrective action. Further layers sit on top of that: unannounced Public Health Service inspections of any awardee institution, USDA APHIS surprise inspections of covered species as often as every six months, and AAALAC accreditation visits at least every three years.

On the human side

Continuing review happens at intervals matched to risk, at minimum annually for ongoing trials, though the 2018 revisions removed that requirement for certain minimal-risk categories. Amendments and modifications need review before they're put into practice, not after.

Documented weak points

The system has been audited and found imperfect, which is worth knowing for anyone reading approval statements as a quality signal. Plous and Herzog reported in 2001 that IACUC decisions did not exceed chance levels of agreement between committees reviewing the same material, and a 2005 USDA Office of Inspector General audit found monitoring gaps tied to member turnover and thin training. On the human side, a 2009 Government Accountability Office undercover test resulted in an IRB approving a fictitious product from a fake company. Committee approval means a protocol cleared a specific process — not that the process is uniform across institutions.

Frequently Asked Questions

Does every laboratory study need IRB or IACUC approval?

No. The trigger isn't that work happens in a laboratory — it's whether the activity meets the federal definition of research involving human subjects or covered animals. A systematic investigation contributing to generalizable knowledge that involves living human participants or their identifiable private information falls under the Institutional Review Board; work with vertebrate animals falls under the Institutional Animal Care and Use Committee. Bench chemistry on a compound in a flask, cell-culture work on commercially available immortalized cell lines, and analytical characterization of a reference material generally fall under neither.

Can a researcher decide on their own that a study is exempt from IRB review?

No, and this is one of the most commonly misunderstood points in the whole framework. "Exempt" is a formal determination the IRB makes, not a conclusion an investigator reaches alone. Even when a study clearly fits one of the federally designated exempt categories, the protocol still has to be submitted so an IRB representative can confirm the exemption before any work starts. Peer-reviewed guidance is blunt about why that sequence matters: retrospective review isn't available, so a missed determination can make otherwise good data unpublishable.

Why are laboratory mice and rats not covered by the Animal Welfare Act?

The Act defines its covered species in a way that excludes birds, laboratory rats of the genus Rattus, laboratory mice of the genus Mus, farm animals in agricultural research, and all cold-blooded animals. Because rodents are by far the most-used research species, the practical effect is that most animal research in the United States sits outside USDA jurisdiction and is governed instead by Public Health Service Policy, which reaches all live vertebrate animals in federally funded work. Institutions holding a Public Health Service assurance extend IACUC review to those species regardless.

Does an IRB or IACUC have any role in work on research-grade chemicals?

Only indirectly. Neither committee reviews the chemistry, purity, or supply of a compound — that belongs to the laboratory's own quality systems and, where a study supports a regulatory submission, to the Good Laboratory Practice regulations at 21 CFR Part 58. The committees enter at the point where a compound would be introduced into a living human participant or a covered animal. For material labeled for research use only, the live compliance questions are about labeling, intended use, and laboratory quality practice instead.

The Bottom Line

IRB and IACUC review are jurisdictional questions before they're paperwork questions. The first thing to establish about any activity is which committee, if any, has authority over it — and that answer comes from the federal definitions of research, human subjects, and covered species, not from where the work physically happens. For laboratory characterization of a research-grade compound, usually neither committee applies, which is exactly why the labeling and intended-use rules carry so much of the compliance weight instead. The intended-use doctrine is the bridge between the two systems, and it's the natural next read for anyone tracking the regulatory side of research-grade material.

For research use only. Not for human or animal consumption of any kind. The information in this article is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. The statements made have not been evaluated by the U.S. Food and Drug Administration. These products are NOT FDA APPROVED. Please consult with a licensed healthcare professional before making any decisions regarding your health or research.

Optides LLC is a chemical supplier. Optides LLC is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic Act. Optides LLC is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic Act.